About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Blood Cancer Discovery
›
top-articles
Blood Cancer Discovery
6.1
(top 5%)
impact factor
321
(top 50%)
papers
2.2K
(top 50%)
citations
26
(top 20%)
h
-index
6.3
(top 5%)
extended IF
368
all documents
2.8K
doc citations
38
(top 20%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma
Blood Cancer Discovery
2020
114
2
Mutational Landscape and Patterns of Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic Leukemia
Blood Cancer Discovery
2020
93
3
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Blood Cancer Discovery
2021
84
4
Revealing the Impact of Structural Variants in Multiple Myeloma
Blood Cancer Discovery
2020
81
5
Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy
Blood Cancer Discovery
2021
71
6
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia
Blood Cancer Discovery
2022
70
7
Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation
Blood Cancer Discovery
2021
64
8
Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies
Blood Cancer Discovery
2021
62
9
T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies
Blood Cancer Discovery
2021
61
10
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors
Blood Cancer Discovery
2021
50
11
COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
Blood Cancer Discovery
2020
46
12
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies
Blood Cancer Discovery
2022
46
13
Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy
Blood Cancer Discovery
2021
44
14
Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia
Blood Cancer Discovery
2020
43
15
Bispecific Antibodies in Multiple Myeloma: Present and Future
Blood Cancer Discovery
2021
43
16
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Blood Cancer Discovery
2021
41
17
Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma
Blood Cancer Discovery
2021
40
18
Genomic Characterization of HIV-Associated Plasmablastic Lymphoma Identifies Pervasive Mutations in the JAK–STAT Pathway
Blood Cancer Discovery
2020
40
19
Integrated Genomic Analysis Identifies
UBTF
Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia
Blood Cancer Discovery
2022
38
20
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma
Blood Cancer Discovery
2022
38
21
SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
Blood Cancer Discovery
2021
37
22
Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy
Blood Cancer Discovery
2021
37
23
NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity
Blood Cancer Discovery
2021
37
24
A Therapeutic Strategy for Preferential Targeting of
TET2
-Mutant and TET Dioxygenase–Deficient Cells in Myeloid Neoplasms
Blood Cancer Discovery
2021
36
25
CD20-Targeted Therapy Ablates
De Novo
Antibody Response to Vaccination but Spares Preestablished Immunity
Blood Cancer Discovery
2022
36
26
Sphingosine-1-Phosphate Receptor 3 Potentiates Inflammatory Programs in Normal and Leukemia Stem Cells to Promote Differentiation
Blood Cancer Discovery
2021
35
27
Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
Blood Cancer Discovery
2022
35
28
Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin Lymphoma
Blood Cancer Discovery
2020
31
29
Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies
Blood Cancer Discovery
2022
31
30
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on
MIR300
Antiproliferative and PP2A-Activating Functions
Blood Cancer Discovery
2020
30
31
Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
Blood Cancer Discovery
2021
30
32
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma
Blood Cancer Discovery
2022
29
33
Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in Healthcare
Blood Cancer Discovery
2021
27
34
Hyperthermia Selectively Destabilizes Oncogenic Fusion Proteins
Blood Cancer Discovery
2021
26
35
Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDS
Blood Cancer Discovery
2021
25
36
Circulating Tumor DNA in Lymphoma: Principles and Future Directions
Blood Cancer Discovery
2022
25
37
Monosomic Loss of MIR15A/MIR16-1 Is a Driver of Multiple Myeloma Proliferation and Disease Progression
Blood Cancer Discovery
2020
24
38
Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Nonmalignant Clonal Hematopoiesis
Blood Cancer Discovery
2021
24
39
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
Blood Cancer Discovery
2022
24
40
Monocytic Differentiation and AHR Signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia
Blood Cancer Discovery
2021
23
41
Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy
Blood Cancer Discovery
2022
23
42
Large-scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers
Blood Cancer Discovery
2021
22
43
Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma
Blood Cancer Discovery
2021
22
44
How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies
Blood Cancer Discovery
2021
22
45
TFEB Links MYC Signaling to Epigenetic Control of Myeloid Differentiation and Acute Myeloid Leukemia
Blood Cancer Discovery
2021
22
46
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
Blood Cancer Discovery
2023
22
47
Apolipoprotein C2 - CD36 Promotes Leukemia Growth and Presents a Targetable Axis in Acute Myeloid Leukemia
Blood Cancer Discovery
2020
21
48
Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators
Blood Cancer Discovery
2021
21
49
An Autochthonous Mouse Model of
Myd88
- and
BCL2
-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities
Blood Cancer Discovery
2021
21
50
Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia
Blood Cancer Discovery
2020
21
site/software ©
exaly
; All materials licenced under
CC by-SA
.